Trial Profile

A randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial of single and multiple ascending doses of KER-065 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KER-065 (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions
Sponsors Keros Therapeutics

Most Recent Events

31 Mar 2025 According to a Keros Therapeutics media release, the company announced initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers
31 Mar 2025 Results published in the Keros Therapeutics media release
03 Jan 2024 According to a Keros Therapeutics media release, the company plans to initiate a proof-of-concept trial of KER-065 in obese patients following completion of this Phase 1 clinical trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com